Gain Therapeutics Inc. (GANX)
NASDAQ · Healthcare
Gain Therapeutics Inc. Long Term Debt 2020–2023
Gain Therapeutics Inc. annual long term debt history from 2020 to 2023. Long term debt refers to financial obligations that are due more than one year in the future.
- Gain Therapeutics Inc. long term debt as of December 31, 2023: 567,850, a 5.89% decrease year-over-year.
- Gain Therapeutics Inc. long term debt for 2023 were 567,850, a 5.89% decrease from 2022.
- Gain Therapeutics Inc. long term debt for 2022 were 603,393, a 13.09% decrease from 2021.
- Gain Therapeutics Inc. long term debt for 2021 were 694,294, a 2.98% decrease from 2020.
- Gain Therapeutics Inc. long term debt for 2020 were 715,656.
Long Term Debt
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Gain Therapeutics Inc. Annual Long Term Debt (Millions of US $) | |
|---|---|
| 2023 | $1 |
| 2022 | $1 |
| 2021 | $1 |
| 2020 | $1 |
Gain Therapeutics Inc. Long Term Debt — FAQ
Gain Therapeutics Inc. (GANX) long term debt over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see GANX's long term debt history?
The chart and table above show Gain Therapeutics Inc.'s long term debt by year and by quarter, including the growth rate.